Appendix
- In patients with moderate-poorly differentiated appendiceal adenocarcinoma undergoing cytoreductive surgery, which systemic therapy sequences and regimens are associated with superior survival and safety outcomes?
- In patients with unresectable pseudomyxoma peritonei, which management approaches offer the best symptom control and survival benefit (surgical interventions vs. systemic therapy vs. conservative management)?
- Is repeat cytoreduction-HIPEC safe and superior to systemic therapy alone or observation for recurrent peritoneal carcinomatosis after initial CRS for appendiceal tumors?
Abstraction Summaries
Appendiceal Prospero Protocols
- Management of Unresectable Pseudomyxoma Peritonei of Presumed Appendiceal Origin: A Rapid Review.Elizabeth Godfrey, Varun Bansal, Craig Gunderson, Forest Mahoney, Kiran Turaga. PROSPERO 2023 CRD42023463230
- Sequence of Systemic Therapy and Cytoreductive Surgery in Appendiceal Adenocarcinoma with Peritoneal Involvement: A Rapid Review.Elizabeth Godfrey, Varun Bansal, Craig Gunderson, Forest Mahoney, Kiran Turaga. PROSPERO 2023 CRD42023463216
Need Accessibility Assistance?
If you are having trouble viewing or accessing this content, please contact David by email.